Scrip Calculation Price

RNS Number : 3439Y
The MedicX Fund Limited
20 February 2013
 



 

 

For immediate release

20 February 2013

 

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

 

Scrip Calculation Price for March 2013 Dividend in relation to the Scrip Dividend Scheme

 

On 17 May 2010 the Board of MedicX Fund Limited announced an opportunity for qualifying Shareholders to receive relevant dividends in new ordinary shares instead of in cash (the "Scheme").

 

In relation to the dividend for the period 1 October 2012 to 31 December 2012 payable on 28 March 2013 (the "March 2013 Dividend"), the price of a new ordinary share in relation to the Scrip Dividend Scheme (the "Scrip Calculation Price") has been set at 77.43 pence. This is the average of the closing middle market quotations for the Company's ordinary shares for the five consecutive business days commencing on the ex-dividend date of 13 February 2013.

 

In order to be valid, Mandate forms must be received by the Company's registrars, Capita Registrars, (or CREST instructions entered) by no later than 5.00 p.m. on 8 March 2013 (the "Mandate Delivery Deadline") in order for elections under the Scrip Dividend Scheme to be effective in relation to the March 2013 Dividend. The Company mailed, on 19 February 2013, personalised Mandate Forms to Shareholders new on the Register since 16 November 2012 and before 15 February 2013 (the "Record Date").  Other Shareholders can use their Mandate Forms issued for previous scrip dividends offered, or obtain Mandate Forms from Capita Registrars.

 

Mandate Forms remain valid for all Relevant Dividends where a Scrip Dividend Alternative is offered, until cancelled. Therefore, Shareholders who have previously completed a Mandate Form but no longer wish to receive a Scrip Dividend should write to Capita Registrars (at the address on page 5 of the Chairman's letter) by no later than 5.00 p.m. on the Mandate Delivery Deadline for the Relevant Dividend to inform them that they wish to revoke the election and receive a cash dividend. 

 

Shareholders who do not wish to receive a Scrip Dividend Alternative and have not previously completed a Mandate Form need take no further action and will receive a cash dividend in respect of the March 2013 Dividend in the usual way. The payment date in respect of the March 2013 Dividend is 28 March 2013. 

 

Shareholders who have any questions regarding the Scrip Dividend Scheme should contact the Capita Registrars helpline on 0871 664 0321*.

 

*Calls made to this number are charged at 10 pence per minute plus network charges. Lines are open 8.30 a.m. to 5.30 p.m. (London time) Monday to Friday (except Bank Holidays).

 

End

 

 

 

For further information please contact:

 

MedicX Group                                                                 +44 (0) 1483 869 500

Keith Maddin, Chairman

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

 

Canaccord Genuity Limited                                                +44 (0) 20 7523 8000

Andrew Zychowski/Helen Goldsmith

 

Buchanan Communications                                               +44 (0) 20 7466 5000

Charles Ryland/Gabriella Clinkard

 

MedicX Fund Limited                                                        +44 (0) 1481 723 450

David Staples, Chairman

 

 

 

Information on MedicX Fund Limited

 

MedicX Fund Limited ("MXF", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 107 properties.

 

The Investment Adviser to the Company is MedicX Adviser Ltd, which is authorised and regulated by the Financial Services Authority and is a subsidiary of the MedicX Group. The MedicX Group is a specialist investor, developer and manager of healthcare properties with 31 people operating across the UK.  

 

The Company's website address is www.medicxfund.com.  Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKKDQOBKDCBB
UK 100